🎉 M&A multiples are live!
Check it out!

Boundless Bio Valuation Multiples

Discover revenue and EBITDA valuation multiples for Boundless Bio and similar public comparables like Galapagos, Benevolent AI, and Pharming.

Boundless Bio Overview

About Boundless Bio

Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.


Founded

2018

HQ

United States of America
Employees

64

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

-$76.8M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Boundless Bio Financials

Boundless Bio has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Boundless Bio achieved revenue of n/a and an EBITDA of -$72.2M.

Boundless Bio expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Boundless Bio valuation multiples based on analyst estimates

Boundless Bio P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$53.8M -$72.2M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$45.9M -$49.4M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Boundless Bio Stock Performance

As of April 15, 2025, Boundless Bio's stock price is $1.

Boundless Bio has current market cap of $27.7M, and EV of -$76.8M.

See Boundless Bio trading valuation data

Boundless Bio Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$76.8M $27.7M XXX XXX XXX XXX $-3.69

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Boundless Bio Valuation Multiples

As of April 15, 2025, Boundless Bio has market cap of $27.7M and EV of -$76.8M.

Boundless Bio's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Boundless Bio's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Boundless Bio and 10K+ public comps

Boundless Bio Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$76.8M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA 1.1x XXX XXX XXX
P/E -0.4x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 1.2x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Boundless Bio Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Boundless Bio Valuation Multiples

Boundless Bio's NTM/LTM revenue growth is n/a

Boundless Bio's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.1M for the same period.

Over next 12 months, Boundless Bio's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Boundless Bio's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Boundless Bio and other 10K+ public comps

Boundless Bio Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 34% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.1M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Boundless Bio Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Boundless Bio M&A and Investment Activity

Boundless Bio acquired  XXX companies to date.

Last acquisition by Boundless Bio was  XXXXXXXX, XXXXX XXXXX XXXXXX . Boundless Bio acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Boundless Bio

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Boundless Bio

When was Boundless Bio founded? Boundless Bio was founded in 2018.
Where is Boundless Bio headquartered? Boundless Bio is headquartered in United States of America.
How many employees does Boundless Bio have? As of today, Boundless Bio has 64 employees.
Who is the CEO of Boundless Bio? Boundless Bio's CEO is Mr. Zachary D. Hornby.
Is Boundless Bio publicy listed? Yes, Boundless Bio is a public company listed on NAS.
What is the stock symbol of Boundless Bio? Boundless Bio trades under BOLD ticker.
When did Boundless Bio go public? Boundless Bio went public in 2024.
Who are competitors of Boundless Bio? Similar companies to Boundless Bio include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Boundless Bio? Boundless Bio's current market cap is $27.7M
Is Boundless Bio profitable? Yes, Boundless Bio is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.